The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 9, 2005, Pages 444-451

  Roy, P ^a   Wangsa, J ^b   Patel, A ^a   Nolting, A ^d   Persiani, St ^c   Abramowitz, W ^a   Kapil, Ram ^a  

^a FOREST RESEARCH INSTITUTE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Rotta Research Laboratorium   (Italy)

^d MSD Sharp and Dohme GmbH   (Germany)

Author keywords

Age and gender; CCK1 receptor antagonist; Dexloxiglumide; Pharmacokinetics

Indexed keywords

CHOLECYSTOKININ A RECEPTOR ANTAGONIST; DEXLOXIGLUMIDE;

ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FACTORIAL ANALYSIS; FEMALE; GROUPS BY AGE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; SEX DIFFERENCE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

EID: 24944554604     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43444     Document Type: Article

References (14)

1. Appel-Dingemanse S, Horowitz A, Campestrini J, Osborne S, McLeod J 2001 The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young. Aliment Pharmacol Ther 15: 937-944
2. Chey W 1993 Hormonal control of pancreatic exocrine secretion. In: Go VL, DiMagno P, Gardner JD, Lebenthal E, Reber HA, Scheele GA (eds): The pancreas: biology, pathobiology and disease. Raven Press, New York, pp 403-424
3. Corp ES, McQuade J, Moran TH, Smith GP 1993 Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. Brain Res 623: 161-166
4. Crawley JN, Corwin RL 1994 Biological actions of cholecystokinin. Peptides 15: 731-755
5. Grider JR 1994 Role ofcholecystokinin in the regulation of gastrointestinal motility. J Nutr 124: 1334S-1339S
6. Innis RB, Snyder SH 1980 Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 77: 6917-6921
7. Niederau C, Luthen R, Heintges T 1994 Effects of CCK on pancreatic function and morphology. Ann NY Acad Sci 713: 180-198
8. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM 2004 The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199: 193-209
9. Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC 2002 Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther 40: 198-206
10. Scarpignato C, Varga G, Corradi C 1993 Effect of CCK and its antagonists on gastric emptying. J Physiol Paris 87: 291-300
11. Setnikar I, Bani M, Cereda R, Chiste R, Makovec F, Pacini MA, Revel L, Rovati LC, Rovati LA 1987 Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneimittelforschung 37: 703-707
12. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G, Miller LJ 1993 Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun 193: 204-211
13. Varga G 2002 Dexloxiglumide Rotta Research Lab. Curr Opin Investig Drugs 3: 621-626
14. Webber C, Roth A, Persiani S, Peard AJ, Makovec F, Kapil RP, John BA, Holding JD, D'Amato M, Cybulski ZR, Chasseaud LF, Rovati LC 2003 Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica 33: 625-641